15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Bio-Rad Laboratories Inc, 1 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $330.00 to $390.00, so the covering firms are broadly aligned. The average target of $350.00 sits 8% below the current $380.25. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $2.91 next quarter toward $10.03 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Moderate Buy
Strong Buy00%
Buy133%
Hold267%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Bio-Rad Laboratories Inc.
As of Sep, 1 of 3 firms rate BIO a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
BIO EPS & revenue forecast
EPS · NEXT QUARTER
$2.91
Range $2.62 – $3.30 · 4 analysts · +16% YoY
Next period, 4 analysts expect Bio-Rad Laboratories Inc to earn $2.91 a share (range $2.62 – $3.30), versus $2.51 a year earlier. Full-year consensus is $9.48, growing to $10.03 the year after.
REVENUE · NEXT QUARTER
$689.9M
Range $677.4M – $699.2M · 4 analysts · -0% YoY
Revenue is expected to reach $689.9M (range $677.4M – $699.2M), -0.5% year-over-year. Full-year consensus is $2.6B, rising to $2.6B next year.
Top analysts covering Bio-Rad Laboratories Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BIO.
#1
Conor McNamara
RBC Capital · Rank #201
Buy
$409.00+7.6% to target
Overall win rate
34%
+ Follow
#2
Patrick Donnelly
Citigroup · Rank #344
Hold
$300.00-21.1% to target
Overall win rate
30%
+ Follow
#3
Brandon Couillard
Wells Fargo
Hold
$290.00-23.7% to target
Coverage
—
+ Follow
#4
DL
Dan Leonard
RBC Capital
Buy
$390.00+2.6% to target
Coverage
—
+ Follow
#5
Daniel Grosslight
Citigroup
Hold
$330.00-13.2% to target
Coverage
—
+ Follow
BIO stock forecast FAQ
What is BIO's average 12-month price target?+
The 3 analysts with a live target average $350.00 for Bio-Rad Laboratories Inc over the next 12 months, ranging from a $390.00 high to a $330.00 low.
Is BIO stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 3 analyst ratings, 1 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for BIO?+
The Street-high target is $390.00 (RBC Capital), and the Street-low is $330.00 (Citigroup). The average of all 3 active targets is $350.00.
How many Wall Street analysts cover BIO?+
3 analysts have an active rating on Bio-Rad Laboratories Inc, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering BIO?+
Among analysts who currently cover BIO, Conor McNamara of RBC Capital has the strongest overall Quantellect track record (Rank #201). Their current call is Buy with a $409.00 target.
What is Bio-Rad Laboratories Inc's projected EPS for next quarter?+
The consensus estimate is $2.91 per share (range $2.62 – $3.30) across 4 analysts. Full-year EPS is projected at $9.48, rising to $10.03 the following year.
How much revenue is Bio-Rad Laboratories Inc expected to report next quarter?+
Consensus revenue is $689.9M (range $677.4M – $699.2M). Full-year revenue is projected at $2.6B, growing to $2.6B next year.
Have analysts been upgrading or downgrading BIO lately?+
As of Sep, 1 of 3 firms rate BIO a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BIO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
Wells Fargo
